Compare Five9 Inc (FIVN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs GSK plc — how do they compare? Five9 Inc trades at $24.81 (market cap $1.90B), while GSK plc trades at $52.73 (market cap $101.34B). The key difference: GSK plc is far larger — about 53.3× Five9 Inc's market cap, and GSK plc pays a 3.49% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | GSK | |
|---|---|---|
Market Cap | $1.90B | $101.34B |
Sector | Technology | Health |
52-Week High | $29.16 | $61.18 |
52-Week Low | $13.61 | $36.20 |
Enterprise Value | $1.98B | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.58, down 0.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $27.00. The company has shown consistent revenue growth, reaching $1.15 billion in 2025, and has beaten earnings estimates for the last three quarters. Recent news highlights include new executive appointments and AI product launches, though some legal scrutiny regarding fiduciary duties exists.
The outlook is positive given strong earnings beats and revenue growth, but risks include high valuation multiples, negative net cash flow, and ongoing legal investigations. Analyst sentiment remains largely bullish, supporting potential upside to the price target.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
